Monday, February 15, 2010
Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection
"There are currently no accurate serum markers for detecting early risk of colorectal cancer (CRC)."
The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews -- Kirkham et al. 340: c365 -- BMJ
"Of the 42 meta-analyses with a statistically significant result only, eight (19%) became non-significant after adjustment for outcome reporting bias and 11 (26%) would have overestimated the treatment effect by 20% or more."
Outcome reporting bias is an under-recognised problem that affects the conclusions in a substantial proportion of Cochrane reviews. Individuals conducting systematic reviews need to address explicitly the issue of missing outcome data for their review to be considered a reliable source of evidence...."
Buchanan sees cancer fight as challenge - Martinsville Bulletin - stage 1C clear cell ovarian cancer (tumour rupture)
"Now, she knows that “unless you’ve truly been there and done that, you cannot truly understand what it is like,” she said. “I’m looking at this as a different phase in my life. If I turn that next corner, I will try to accept the things I cannot change and deal with it the best I know how. It will make me a stronger person.”
Confusing association with causation - common journalistic pitfall - Gary Schwitzer's HealthNewsReview Blog
"We've just posted a new guide on the importance of the language used to describe the results of observational studies. Day after day we see stories that use active powerful verbs like "prevent...boost...lower your risk...may cut death rate" to describe the results of these studies. That's misleading and inaccurate because such studies can't prove cause-and-effect. Read more about why in this detailed, thoughtful piece by Mark Zweig, MD, and Emily DeVoto, PhD. (It's actually a revision of a piece these two wrote for us two years ago. The new one fits nicely in our "Tips for Understanding Studies" section.)"
in research: "This is often the fatal process in breast, ovarian, pancreatic and colon-rectal cancers."
Note: this rather large paper includes cancer and international comparisons
Social Science & Medicine : End of Life Care Policies: Do they make a difference in practice? (analysis - Saskatchewan, Canada)
"The findings of this study demonstrate a significant gap between institutional End of Life care policies and practice..."
Surgical Oncology Clinics of North America, Volume 19, Issue 2, Pages 235-462 (April 2010)
Pancreatic Cancer: Current Concepts in Treatment and Research
Sunday, February 14, 2010
Please take the poll and add your views on this issue.............................................
Conclusion: "The majority of patients wish to help medical students to learn but expect consent to be sought if medical students are to perform pelvic examinations on anaesthetized patients. Before introducing explicit consent in Canadian teaching centres, it will first be necessary to determine the feasibility of seeking consent specifically for this procedure."
- I am happy to help with learning 24 (31%)
- I do not feel permission is need 0 (0%)
- Permission is needed sometimes 1 (1%)
- Permission is needed without except 71 (93%)
- I have no concerns with the ethics of this situation 1 (1%)
- I have great concerns with the ethics of this situation 68 (89%)
- Is this today common practice - pelvic exams while under anesthesia? 22 (28%)
- Yes (common practice) 6 (7%)
- No (common practice) 7 (9%)
- How would I know? (common practice) 29 (38%)
- Is this a trust issue? 17 (22%)
- I belong to the ACOR ovarian group 35 (46%)
- I am a medical professional 11 (14%)
- Yes, I read the article 47 (61%)
- No, I didn't read the article 15 (19%)
- Was this new information for patients? 15 (19%)
- Was this new information for healthcare professionals? 13 (17%)
a caution regarding Curcumin (partial abstract)
Sunday, February 14, 2010
Poll is Open
please contribute your views (men & women)
Patients, Consumer and Health Care Professionals
Note: This issue of pelvic exams while under anasethesia has been explored in the research in the past (click on 'read more' to see viewers comments)
Please take the poll and add your views on this issue.............................................
* research abstract: "Teaching Pelvic Examinations Under Anaesthesia: What do Women Think" by Sara Wainberg from the Journal of Obstetrics&Gynecology http://www.sogc.org/jogc/abstracts/2010
* "Time to end pelvic exams done without consent" The Globe&Mail http://www.theglobeandmail.com/life/health/time-to-end-pelvic-exams-done-without-consent/article1447337/
* "When unknowing, hardly implied" The Globe&Mail Editorials http://www.theglobeandmail.com/news/opinions/editorials/when-unknowing-hardly-implied/article1451312/
(2007) full access: Twin births, sex of children and maternal risk of ovarian cancer: a cohort study in Norway
Cigarette Smoking as a Cause of Cancers Other Than Lung Cancer: An Exploratory Study Using the SEER Program — CHEST
Saturday, February 13, 2010
"Does this mean you should avoid CT scans? No, don't swing from scan-a-mania to scan-a-phobia. These tests can be lifesavers, provided you and your doctor use them only when the benefits outweigh the risks....."
Powerpoint presentation: Opioid-Induced Constipation: Banishing a Barrier to Successful Pain Management
see the section: "Download the Slide Presentation"
Medical News: Gabapentin Studies for Off-Label Uses Cooked? - in Neurology, Pain Management from MedPage Today
"Because the outcomes we examined were fiddled with to some extent, we don't know what the outcome was for the primary outcome that was originally set," she said.
"If I were a physician, or a patient, I would be thinking, what is the true evidence base here?"
Friday, February 12, 2010
"Studies such as that by Ueda and colleagues offer hope to patients with cancer that in the future they will be offered truly tailored treatment, based on the unique biology of their tumour as defined by microRNAs."
"This type of study needs to be done for every cancer type."
MRI of Endometriotic Cysts in Association With Ovarian Carcinoma -- Tanaka et al. 194 (2): 355 -- American Journal of Roentgenology
CONCLUSION. Endometriotic cysts with enhanced mural nodules are not always complicated with malignancy. In elderly patients, the presence of large enhanced nodules on large endometriotic cysts is more likely to indicate malignancy.
Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype -- Journal of Clinical Pathology
Conclusion: Preoperative CA19.9 levels cannot be used to predict whether a suspected ovarian mucinous tumour is benign, borderline or malignant. Markedly elevated serum levels (>1000 U/ml) may be found in benign mucinous neoplasms as well as in borderline and malignant tumours.
Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot stud
Note: warning on stats
"Results: Overall, 36 OCR patients were enrolled. The majority of the patients (>80%) were classified as platinum resistant.....
Prospective phase III trials are warranted to evaluate the benefit and efficacy in heavily pre-treated patients with OCR."
CONCLUSION: A standardized definition of adverse events in the homecare setting is needed. Prospective cohort studies are needed to improve estimates and intervention studies should be undertaken to reduce the risk that homecare patients will experience adverse events.
PharmaLive press release: Clinical Science to publish manuscript on HTX005 ovarian cancer biomarker 'OvPlex' (plus HTX005/AGR2)
Note: the abstract included here did not indicate the number of patients involved in the studies (see prior research articles) but according to the press release showed results in stages 11/111.
"10 February 2010, Melbourne: HealthLinx Limited (ASX:HTX) has been notified by the journal Clinical Science that a manuscript submitted for review by HealthLinx scientists and collaborators at the University of Liverpool has been accepted for publication. The manuscript describes the identification of HTX005 (AGR2) as a novel biomarker released into the bloodstream of ovarian cancer patients.
The performance of the novel biomarker AGR2 will be further tested in an up-coming multi-centre, multi-national biomarker study planned by HealthLinx. Based on preliminary data it is expected that this biomarker will increase the performance of OvPlex™ to greater than 97 per cent."
Antibodies Against Abnormal Glycoproteins Identified as Possible Biomarkers for Cancer Detection, February 2, 2010 News Release - National Institutes of Health (NIH)
The team used this approach to screen blood specimens from breast, ovarian and prostate cancer patients.
Thursday, February 11, 2010
"The University of Kansas Cancer Center began running a Phase I clinical trial of the anti-ovarian cancer drug Nanotax. Nanotax is a breakthrough drug because, unlike other anti-cancer drugs, it is water-soluble....The clinical trial at the University comes nearly 15 year after Nanotax was first conceived. It is one of three active clinical trials for ovarian cancer treatment in Kansas, and it’s the only one still recruiting patients. The trial is classified as Phase I because it tests the drug in a small group.
Prevalence Rates of Pathogenic Mutations in the BRCA1 and BRCA2 Genes in Families with Different Disease Histories: Results from the German Consortium for Hereditary Breast and Ovarian Cancer
* From 1997-2009 more than 6,000 families were screened for pathogenic mutations in BRCA1/2.
"Among women, an increased rate of mortality was observed both for deficient concentrations and very high concentrations (>124nmol/L). Results suggest that caution should be exercised in using very high dose vitamin D supplementation in prevention trials that may result in high concentrations of vitamin D (>100nmol/L). Results suggest that caution should be exercised in using very high dose vitamin D supplementation in prevention trials that may result in high concentrations of vitamin D (>100nmol/L)."
Abstract - Cancer predisposition: I say genetics, you say genomics, but are we there yet? -- Cancer Prevention Research
"A few examples include Lynch syndrome, hereditary breast-ovarian cancer syndrome and Cowden syndrome."
Abstract: Risk factors for epithelial ovarian cancer by tumor dominance, a surrogate for cell of origin -Cancer Prevention Research
"Although limited by small case numbers, our results suggest that tubal ligation may be more strongly associated with tumors of ovarian origin, while family history of ovarian cancer primarily increases risk of tumors of tubal origin. Characterizing risk factor relationships by tumor dominance may elucidate how these exposures alter risk and help to improve prevention efforts."
Abstract Public and provider awareness and use of a CA-125 test for ovarian cancer -- - Cancer Prevention Research
"Participatory Medicine is a cooperative model of health care that encourages and expects active involvement by all connected parties (patients, caregivers, healthcare professionals, etc.) as integral to the full continuum of care. The ‘participatory’ concept may also be applied to fitness, nutrition, mental health, end-of-life care, and all issues broadly related to an individual’s health."
Wednesday, February 10, 2010
news item - court case - Charleston woman names physician, practice in medical negligence case | West Virginia Record
Note: this article does not mention what type of cancer although it references gynecologic oncology
SGO Tumor Board Discussant presentation on Ovarian Cancer Neoadjuvant Chemotherapy by Ignace B. Vergote, MD, PhD, University Hospital Leuven, Leuven Belgium
Clinical Presentation - 2/2009 (freely accessible) slide and subsequent discussion presentation on debulking procedures/neoadjuvant vs upfront surgery, maintenance therapies comparing outcomes in European/Central American/Canadian studies etc
Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse — Dr Maurie Markman et al
Note: very short abstract as below, but good points (in the absence of the full paper)
"Unlike other diseases, dose-selection for cancer therapeutics is often based on the maximum-tolerated dose in phase 1 studies involving relatively few patients. In this issue of Clinical Cancer Research, Jain and colleagues provide evidence that lower doses may be as effective as maximum-tolerated doses in the treatment of cancer patients."
"This special session for survivors will provide updates on emerging research, as well as information about patient resources. Women and their families will have the opportunity to “Ask the Expert” as well as network with other individuals sharing the same experience. Please watch this space for detailed program updates."
Editorial note (mine): colour me stupid, but at last check turquoise was not/is not teal
"With turquoise being the colour of the year, this provides us with the perfect opportunity to continue to create awareness about ovarian cancer, the deadliest of all gynecologic cancers. Celebrate our colour throughout 2010 – wear it often, tell your friends and paint your town teal!"
Abstract/full access: What physicians want to learn about sickness certification: analyses of questionnaire data from 4019 physicians
"A majority of physicians in most types of clinics/practices, not only primary care, indicated the need for more knowledge and skills in handling sickness certification cases. Increased knowledge and skills are needed in order to protect both the health and equity of patients. However, few physicians stated that they needed more skills in filling out sickness certificates, which contradicts previous findings about such documents being of poor quality and suggests that factors other than mere knowledge and skills are involved."
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study (Paroxetine/Paxil/Seroxat)
CONCLUSION: Paroxetine use during tamoxifen treatment is associated with an increased risk of death from breast cancer, supporting the hypothesis that paroxetine can reduce or abolish the benefit of tamoxifen in women with breast cancer. (trade names Seroxat, Paxil)
Blog: What Reporters Missed at the NIH Colon CA Screening State-of-the-Science Conference By: Gary Schwitzer
"....And it's difficult to understand why this didn't get news coverage. It sure sounded newsworthy to me."
"I do not want my life to be prolonged if, to a reasonable degree of medical certainty, my situation is hopeless."
"I want my life to be prolonged as long as possible within the limits of generally accepted medical standards, even if this means that I might be kept alive on machines for years."
"Check one. That's one of the places where I'm stalled on making my advance medical directive."
Augmentation of Therapeutic Efficacy in Drug-Resistance - breast and ovarian cancers - C6 (CER) + Paclitaxel
"This study describes a novel mechanism to overcome MDR through a polymer-blend nanoparticle platform that delivers a combination therapy of C6-ceramide (CER), a synthetic analog of an endogenously occurring apoptotic modulator, together with the chemotherapeutic drug paclitaxel (PTX), in a single formulation. ( PTX/CER )
Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds -- Grindedal et al. 47 (2): 99 -- Journal of Medical Genetics
Conclusions: In the series examined, infiltrating ovarian cancer in Lynch syndrome had a better prognosis than infiltrating ovarian cancer in BRCA1/2 mutation carriers or in the general population. Lifetime risk of ovarian cancer of about 10% and a risk of dying of ovarian cancer of 20% gave a lifetime risk of dying of ovarian cancer of about 2% in female MMR mutation carriers.
Tuesday, February 09, 2010
Note: refers to time spent by genetic counselors in advising patients
CONCLUSIONS: Severe ovarian damage, occurring in gonads operated on for ovarian endometriomas, is not a rare event.
"Patients taking Paxil and tamoxifen should talk with their doctors about changing their antidepressant, Juurlink said. But he advised against abruptly discontinuing Paxil.
"There is a very real danger to stopping Paxil suddenly. There is a well-described withdrawal syndrome and the risk of depression becoming more severe," he said.
In addition, any transition to another antidepressant should be done gradually over several weeks, he said."
Monday, February 08, 2010
Note: the OVATURE ovarian cancer trial results are to be published later this year - Phenoxodiol
"Trust in a “person like yourself” has decreased from 2008 to 2009 (as have most information sources listed in the report), and dropped again in 2010. From the global 2010 Edelman report, 44% of respondents aged between 25-64 years said they would find the information from a person like them to be either ‘very credible’ or ‘extremely credible’ (down from 47% in 2009, and 58% in 2008). That’s a huge drop over the past 3 years!......Another point to keep in mind is that a “person like yourself” is not the same as a “patient like yourself”. "
Sunday, February 07, 2010
2009 A Pan-Canadian Clinical Practice Guideline: Assessment of Psychosocial Health Care Needs of the Adult Cancer Patient
1) next update is 2014;
2) a quick search reveals that data was:
included for: breast,colorectal,lung,prostate
not included for: ovarian,brain,pancreatic,leukemia,lymphoma
DNA stool test A DNA stool test screens stool for DNA mutations, indicating the presence of precancerous polyps or colon cancer"
* Pros: No dietary changes are required before the test. There’s no need to empty the colon ahead of time. Stool sample collection can be done at home.
* Cons: The test currently screens for a limited number of DNA mutations in stool. The test hasn’t been universally accepted as a screening tool for colon cancer. False-negative results are possible.
Search of: ovarian cancer | Adult | received from 01/01/2010 to 02/07/2010 - List Results - ClinicalTrials.gov
Search of: 'ovarian cancer' received from 01/01/2010 to 02/07/2010 - List Results = 11
Risk-reducing bilateral salpingo-oophorectomy (RRSO) is an effective option for women with BRCA mutations however there is limited information as to how much tubal epithelium remains after RRSO.
Saturday, February 06, 2010
Conclusion. Preoperative serum TN is a useful prognostic indicator of advanced stage for patients with OvCa.
Conclusion:"Australian gynaecologic oncologists experience considerable occupational distress while possessing high levels of personal accomplishment and job satisfaction. To maintain a healthy workforce, it is important to build on existing supports while conducting further research to identify suitable evidence-based strategies for improving the mental health of these surgeons."
Conclusions:"Although during the introductory period nerve-sparing technique brings about an improvement in voiding function, it prolongs the total operative time in comparison to traditional radical hysterectomy."
"In our study population, introduction of the RMI would improve the management of adnexal masses, with a higher percentage of ovarian cancer patients that are operated by a gynecologic oncologist. At the same time, referral of patients with non-invasive (benign and borderline) lesions would be reduced."
When ‘never-events’ occur despite adherence to clinical guidelines: The case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes
Note: 'never-events' is a term used in patient safety (eg. language - near misses, etc)
"Women with CCC-O have a 2.5-times greater risk of disease related VTE than women with other histologies of epithelial ovarian cancer despite adherence to prophylactic guidelines. Given the high rate of VTE postoperatively as well as with disease recurrence, one should consider indefinite therapeutic anticoagulation in women with CCC-O. The case of CCC-O is one example of the impracticality of payment denial for ‘never-events,’ as VTE arises despite best efforts at prevention."
Conclusion: Intraperitoneal chemotherapy regimens using carboplatin or cisplatin and dropping day 8 IP paclitaxel have less toxicity and less discontinuation of therapy
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG (S0200) phase 3 randomized trial
Conclusion: "Despite a favorable impact of carboplatin and PLD on progression-free survival in this trial, the effect on overall survival is not statistically significant. For currently unknown reasons, administering PLD with carboplatin appears to substantially reduce the incidence of platinum-associated hypersensitivity reactions."
BACKGROUND: One of the cornerstones of ovarian cancer therapy is cytoreductive surgery, which can be performed by surgeons with different specialty training. We examined whether surgeon specialty impacts quality of life (as proxied by presence of ostomy) and overall survival for women with advanced ovarian cancer.
abstract: Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: The big picture
"We propose that future international cooperation should aim at a uniform pooled analysis of the wealth of ovarian cancer array data already available. This will enhance the power of each separate ovarian cancer study and can lead to promising results."
"A novel finding, described Feb. 4 on the Science Express Web site by teams from the National Cancer Institute, The University of Texas Health Science Center at San Antonio and the University of Toronto, offers a clue as to how genes can have what you might call multiple personalities...."
Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: A Multicenter Phase II Trial
ConclusionThe combination of PLD and continuous IFO is a feasible and efficient treatment in patients with relapsed ovarian cancer, especially with TFI between 6 and 12 months. This regimen may represent an alternative to platinum reintroduction and should be evaluated in a randomized trial.
Survival after recurrence in early-stage high-risk epithelial ovarian cancer: A Gynecologic Oncology Group study
ObjectiveThis study aimed to evaluate the clinical outcome of recurrent early-stage high-risk epithelial ovarian cancer patients.
The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: An exploratory analysis of a Gynecologic Oncology Group study
Abstract Objectives A prior clinical trial on early-stage high risk ovarian cancer showed a lower recurrence rate in those treated with six vs. three cycles of chemotherapy. We proposed to identify subsets of patients who may benefit from more cycles of chemotherapy.
abstract: From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer
Note: patients enrolled between January 2006 to December 2007 "Background: The objective of the study was to evaluate completion rates and toxic effects of an i.p. chemotherapy regimen in a cross-section of nonselected patients with ovarian cancer (OC). Conclusions: The i.p. chemotherapy regimen used in a consecutive cohort of patients carries could be completed in only a small percentage of patients. Less toxic regimens with higher acceptability should be considered."
Chemotherapy Resistance as a Predictor of Progression-Free Survival in Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy and Surgical Cytoreduction Followed by Intraperitoneal Chemotherapy: A Southwest Oncology Group Study
re: tumour assay testing
"Conclusions: While the small patient numbers in this trial do not permit definitive conclusions, these data fail to provide support for the argument that prospectively obtained in vitro data regarding platinum or paclitaxel resistance will be highly predictive of clinical outcome in advanced ovarian cancer."
Oncogene - Abstract (technical): Cadherin switching and activation of p120 catenin signaling are mediators of gonadotropin-releasing hormone to promote tumor cell migration and invasion in ovarian cancer
Definition: Cadherins - (Calcium dependant adhesion molecules) are a class of type-1 transmembrane proteins. They play important roles in cell adhesion.
Definition: Gonadotropin - hormone secreted by the anterior pituitary gland and placenta; stimulates the gonads and controls reproductive activity. A hormone that stimulates the ovaries (such as to produce estrogen).
"These results identify for the first time cadherin switching and p120ctn signaling as important targets of GnRH function and as novel mediators of invasiveness and tumor progression in ovarian cancer."
Not telling the truth: circumstances leading to concealment of diagnosis and prognosis from cancer patients
Dying at home: community nurses' views on the impact of informal carers on cancer patients' place of death European Journal of Cancer Care
Note: abstract; one of the few articles which challenges mainstream research discussing the issues of dying at home and the wishes of patients/caregiver.
HTML Full Text - Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours
(included ovarian cancer patients in study)
In Research: Oncolytic (replication-competent) adenoviruses as anticancer agents; Expert Opinion on Biological Therapy
Friday, February 05, 2010
"Other industries responsible for public safety (e.g., the transportation and nuclear power industries) have been subject to federal regulations that limit the number of hours their employees can work for decades."
Expected Number of Awards: 12
Estimated Total Program Funding: $4,100,000
NEW for FY10, the OCRP Translational Pilot Award mechanism supports innovative translational research addressing a critical problem or question in ovarian cancer that will accelerate the movement of promising ideas toward clinical applications.
"The American Society for Radiation Oncology (ASTRO) and the American College of Radiology (ACR) have released practice guidelines for image guided radiation therapy (IGRT) and stereotactic body radiation therapy (SBRT) in the February issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO."
Surgical Mesh - Complications Associated with Transvaginal Implantation of Surgical Mesh for the Treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse - Notice to Hospitals
Note: warnings on surgical mesh complications exist for other procedures as well (search adverse events reports)
Thursday, February 04, 2010
Subject: Cochrane Canada Symposium Workshop: Cochrane Canada 8th Annual Symposium - Evidence in Uncertain Times: Meeting the Challenge Date: 19-20 May 2010, Presymposium: 17-18 May 2010 Location: Ottawa, Ontario, Canada Details: We invite researchers, health policy makers and managers, health professionals, and patients to join the Canadian Cochrane Centre as we discuss Evidence in Uncertain Times at our 8th annual symposium. Abstract submission for workshop, oral and poster presentations is open until 12 February 2010. Early Bird registration ends on 19 March 2010 Email: email@example.com Website: www.ccncsymposium.com
World Journal of Surgical Oncology | Full text | A case of Meigs syndrome mimicking metastatic breast carcinoma
Rare ovarian tumours: therapeutic strategies in 2010, national website observatory for rare ovarian cancers and delineation of referent centers-France
Note: ignore the small spelling errors in the article as it was translated from French to English
(abstract) FOCUS REVIEW
MicroRNAs in ovarian carcinomas
Neetu Dahiya1 and Patrice J Morin1,2
1 Laboratory of Cellular and Molecular Biology, National Institute on Aging, NIH Biomedical Research Center, 251 Bayview Boulevard, Suite 100, Room 6C228, Baltimore, Maryland 21224, USA
2 Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
Phase 1Trial Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer - Full Text View - ClinicalTrials.gov
"Genetic researchers prevent genes from performing their function, "knocking down" the gene, by inserting small interfering RNA (siRNA) molecules into the cells. The next steps in the team's research will be to examine the effect of siRNA in ovarian cancer samples in the lab, and to test the technique on mice."
There are a number of slide presentations (free full access)
Note: that there is an overlap here with Lynch Syndrome
"This syndrome is defined as the coexistence of sebaceous adenomas, sebaceus carcinomas, keratoacanthomas, and pedunculated tumors, some with lobulated structure. The cutaneous involvement (sebaceous gland tumor) is associated with at least a single internal malignancy; mostly colonorectal or genitourinary malignancies."
Medical News: Hidden Dangers of Herbal Meds Reviewed - in Primary Care, Alternative Medicine from MedPage Today
discusses some of the negative interactions
Wednesday, February 03, 2010
Ideal Candidates for the NCI Director's Consumer Liaison Group:
Ideal candidates must:
1. have first-hand knowledge of the cancer experience;
2. be affiliated with a cancer-related constituency; and
3. possess relevant non-scientific skills and perspectives that will allow them to help improve research outcomes by identifying new approaches, promoting innovation, recognizing unforeseen risks or barriers, and identifying unintended consequences that could result from NCI decisions.
Note: ACOR ovarian cancer members - the report will be in the archives - Commonwealth Fund
Journal of Chemotherapy 2009 full access: What is the Benefit of 'Avastin' Combined with Chemotherapy in Patients - recurrent Ovarian, Primary ....
Journal of Chemotherapy 2009 full access: What is the Benefit of 'Avastin' Combined with Chemotherapy in Patients - recurrent Ovarian, Primary Peritoneal, Fallopian Tube Cancers.
Note: 64 patients in study; descriptive (stage 1C+); stage 1/11=4 pts; clear cell (2);endometrioid (3); mucinous (2);platinum resistant; side effects....(paper takes time to download)
Cochrane Collaboration Review: Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy for the prevention of lymphocyst formation in patients with gynaecological malignancies
Placement of retroperitoneal tube drains has no benefit in prevention of lymphocyst formation after pelvic lymphadenectomy in patients with gynaecological malignancies. When the pelvic peritoneum is left open, the tube drain placement is associated with a higher risk of short and long-term symptomatic lymphocyst formation.
Note: p53 gene/cancer implications
Chemotherapy Resistance as a Predictor of Progression-Free Survival in Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy and Surgical Cytoreduction Followed by Intraperitoneal Chemotherapy: A Southwest Oncology Group Study
Antibodies Against Abnormal Glycoproteins Identified as Possible Biomarkers for Cancer Detection press release - National Institutes of Health (NIH)
"The team used this approach to screen blood specimens from breast, ovarian and prostate cancer patients....They found distinct abnormal mucin-type O-glycopeptide epitopes (parts of molecules that antibodies will recognize and bind to) that were targeted by autoantibodies in cancer patients — but such antibodies were absent in healthy controls.....Although larger sets of specimens will have to be analyzed to fully appreciate the clinical value of this technology, the preliminary results are very promising.The study was an international collaboration that was funded in part by NCI through the trans-NIH Alliance of Glycobiologists for Detection of Cancer and Cancer Risk."
Stanford's Canary Center strives to find cancer sooner than every before - 2/01/10 - San Francisco News
"Scientists at the Canary Center say their first blood test, developed for ovarian cancer, is about to begin phase one clinical trials at Stanford. The first patient group will be women at high risk for ovarian cancer."
includes reference to ovarian cancer
....legally binding international convention that would outlaw human rights violations in end-of-life decision-making.
"What if a patient—after diagnostic tests have been performed and there is no more certainty to obtain—still has a 1 in 100 chance of having venous thromboembolism (VTE)? Should the patient's physician engage the patient in a discussion of the harm and benefit of anticoagulation? What if the chance of VTE was 1 in 20? Or even 1 in 10?"
Effectiveness of a home care nursing program in the symptom management of patients with colorectal and breast cancer receiving oral chemotherapy
Note: includes professional commentaries; Implications for all patients ($$)
"It's very frustrating for patients and for researchers that there hasn't been significant advances in ovarian cancer," says Dr. Tanja Pejovic, a gynecologic oncologist and associate professor at Oregon Health & Science University......Pejovic's group at OHSU is among those seeking to understand the basic biology as a means to zero in on likely markers of early disease. In a study reported in December, the group monitored the action of 69 genes in cells that make up the ovarian surface epithelium. They identified a set of genes that appear to become more active as cells progress from normal to cancerous......"We are still trying to understand early events," she says. But Pejovic remains optimistic."We have to understand early events to the point where it can lead us to markers that circulate in the blood."
Reuters Health Information (2010-02-02): Simple ovarian cysts not linked to cancer in postmenopausal women
"Women with and without simple cysts were at similar risk of invasive ovarian cancer after nearly 8 years of follow-up evaluation, the authors write. Furthermore, traditional ovarian cancer risk factors, such as increasing age, family history of breast or ovarian cancer, nulliparity, and infertility, were not associated with simple cysts. Finally, changes in average CA-125 were not correlated with increases in the number or progression of simple cysts.Thus, Dr. Greenlee and his group conclude, "Simple cysts are not likely cancer precursors or markers of increased risk and can be followed conservatively.""
The c.509_510delGA is a novel PALB2 mutation that increases the risk of familial breast cancer. Occurrence of the same PALB2 alteration in seven unrelated women suggests that c.509_510delGA (p.R170fs) is a recurrent mutation for Polish population.
Tuesday, February 02, 2010
Note: this study also discusses tumour rupture/survival; the abstract does not include specific cell types, however, clear cell can be possibly presumed given the research data on Japanese women with clear cell ovarian cancer.
Patient with Eight Metachronous Gastrointestinal Cancers Thought to be Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Lynch Syndrome.
Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.
Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Note: The response rates in this study either alone or in combination were low. The side effects appear to be understated (abstract).